文献速递中药与中成药合理使用

CONSORT-CHM配方2017在中药复方随机对照试验中的依从性评估:五年综述方案

Evaluation of compliance of CONSORT-CHM formula 2017 in randomized controlled trials of Chinese herbal medicine formulas: protocol of a five-year review.
PubMed 文献 · Front Pharmacol · 2024-02-23

本方案计划系统检索2018年1月1日至2022年6月8日发表的中药复方干预随机对照试验,评估其对CONSORT-CHM配方2017的依从性。将清单22个扩展条目细分为42个子问题,计算依从率,以识别报告质量现状并评估指南影响。

要点

  • 系统评估近5年中药复方RCT对CONSORT-CHM配方2017的依从性。
  • 将22个条目细分为42个子问题,重点评估描述、质量控制与安全性。
  • 采用双人背对背评估并计算依从率,确保一致性。

核心结论

  • 本综述将识别中药复方干预研究的报告特征与质量,并评估CONSORT-CHM配方2017的影响。
  • 结果可能为该指南的未来应用或推广提供建议。

研究设计与样本

  • 系统检索EBM Reviews、AMED、Embase、Ovid-MEDLINE(R)、万方、CNKI、VIP和CBM数据库。
  • 纳入2018年1月1日至2022年6月8日发表的中药复方干预RCT,语言限英文或中文。
  • 将CONSORT-CHM配方2017清单的22个扩展条目细分为42个子问题以便评分。
  • 对100篇随机抽取的文章进行专业培训和预试验,并制定质量评估标准操作程序(SOP)。
  • 每项由两名评价员以配对背对背方式评估,计算依从率以评估评价者间一致性。

关键数值与推荐

  • CONSORT-CHM配方2017清单由22个扩展条目组成,细分为42个子问题。
  • 评估重点关注中药复方干预的描述、质量控制与安全性评估。
  • 依从率将用于评估评价者间一致性。

临床怎么用

  • 可通过依从率识别中药复方RCT报告中的薄弱环节,指导未来研究设计与报告。
  • 评估结果可为指南的推广与应用提供依据。

局限性

  • 本方案为综述计划,尚未报告实际评估结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: The CONSORT Extension for Chinese Herbal Medicine Formula 2017 (CONSORT-CHM Formula 2017) has established a reporting standard for randomized controlled trials (RCTs) of Chinese Herbal Medicine Formula (CHMF) interventions; however, its adherence and implications for the design and execution of study design remain ambiguous. It is necessary to evaluate the level of compliance with the CONSORT-CHM Formula 2017 in RCTs conducted over the past 5 years, and to determine the reporting quality of clinical trials in this field. Methods: First, a systematic search is conducted for RCTs on CHMF in EBM Reviews, Allied and Complementary Medicine (AMED), Embase, Ovid-MEDLINE(R), Wanfang data, China National Knowledge Infrastructure (CNKI), VIP Chinese Medical Journal Database (VIP) and Chinese Biomedical Literature (CBM) database, that encompassed CHMF interventional RCTs published from 1 January 2018 to 8 June 2022, with language restriction to English or Chinese. Second, a descriptive analysis will be performed regarding the study design and general characteristics of the included trials. Third, for the quality assessment, we have subdivided the CONSORT-CHM Formula 2017 checklist (consisting of 22 extended items) into a total of 42 sub-questions to facilitate scoring, with a specific focus on the description, quality control, and safety assessment of CHMF interventions. Professional training and a pilot test on 100 randomly selected articles will be provided for all reviewers. Throughout this process, a standard operating procedure (SOP) for quality assessment will be developed to ensure consistency. Each item will be assessed by two reviewers in a paired back-to-back manner, and the compliance rate will be calculated to assess inter-rater agreement. Discussion: This review will identify the current reporting characteristics and quality of CHMF interventional studies and further evaluate the impact of CONSORT-CHM Formula 2017. The results may provide suggestions for future application or promotion of the guideline. Registration: The study has been registered on Open Science Framework (https://osf.io/xpn7f).

来源:Front Pharmacol,查看原文。版权归原作者所有。

引用

  1. Wang J, Cheng CW, Jiao Y, et al. Evaluation of compliance of CONSORT-CHM formula 2017 in randomized controlled trials of Chinese herbal medicine formulas: protocol of a five-year review. Front Pharmacol. 2024. PMID: 38464724. doi:10.3389/fphar.2024.1287262

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。